Debiopharm Reinforces The Bond Between Swiss And Japanese Cancer Research With The 2022 Jca Mauvernay Award Ceremony
PR98117
LAUSANNE, Switzerland , Oct. 3, 2022 /PRNewswire=KYODO JBN/--
Debiopharm ( www.debiopharm.com ), a Swiss-based global biopharmaceutical
company, today announced the two winners of JCA Mauvernay Award for
breakthrough Japanese oncology research projects in 2 categories: Innovative
and/or Disruptive Research – Dr. Akihide Yoshimi and for Translational Research
– Prof. Mamiko Sakata-Yanagimoto. The winners were honored with trophies and a
monetary prize during the live event of the 81st Annual Meeting of the Japanese
Cancer Association (JCA) on Saturday, October 1st in Yokohama, Japan by Prof.
Hideyuki Saya President of the JCA and Thierry Mauvernay, President of
Debiopharm, and Bertrand Ducrey CEO of Debiopharm.
"Japan and Switzerland share a variety of similar values such as commitment to
excellence and professional diligence. With these values, we can maximize the
chances that the next generation of drugs could result from collaboration
between these two countries." expressed Thierry Mauvernay, President of
Debiopharm. "Together with the JCA, Debiopharm hopes to encourage young
scientists such as Drs Yoshimi and Sakata-Yanagimoto, to transfer their
innovative research to the clinic and to the benefit of worldwide patients
rapidly."
"The previous winners of the Mauvernay Award have immediately become very
well-known scientists in our country, becoming professors and leaders in
significant institutes. Therefore, I would say that the Mauvernay Award is
definitely a huge step for young cancer research scientists in our country."
stated Prof. Hideyuki Saya, President of the JCA.
Dr. Akihide Yoshimi's disruptive research at the National Cancer Center
Research Institute, is aimed at understanding and targeting aberrant RNA
splicing in hematological malignancies. He has contributed to the discovery of
aberrant events in this process in tumor cells, identified key alterations in
several splicing factors (SF) and provided insights into aberrant splicing and
its association with key oncogenes (such as isocitrate dehydrogenase (IDH) and
myelocytomatosis (Myc)). This work within an emerging field could have
important biological as well as therapeutic implications for patient with SF
mutant hematologic malignancies (e.g. in acute myeloid leukemia (AML), chronic
lymphocytic leukemia (CLL), chronic myelomonocytic leukemia (CMML) and
myelodysplastic syndrome (MDS)).
Prof. Mamiko Sakata-Yanagimoto's translational research at the Medicine Faculty
of the University of Tsukuba is offering new insights into targeting
intractable lymphomas with an elegant application of gene expression analysis
in the aggressive angioimmunoblastic lymphoma (AITL). Her research started with
the characterization of sequence of events between TET2 and RHOA mutations in
the AITL patient samples (now included in the diagnostic criteria), continued
with the identification of new actionable targets in the disease (RHOA/Vav1)
and is currently focused on testing in the clinic therapeutic options using
dasatinib to treat those patients.
The JCA-Mauvernay Award
Since 2005, the Japanese Cancer Association (JCA) and Debiopharm have
co-organized the 'JCA-Mauvernay Award'. This prize illustrates the curiosity
that drives researchers as well as the scientific cooperation between Japan and
Switzerland. It aims to recognize the outstanding achievements in the field of
oncology amongst Japanese researchers, in both the fundamental and the clinical
aspects. The award has a total value of CHF 25'000.
Debiopharm's commitment to patients
Debiopharm develops innovative therapies that target high unmet medical needs
in oncology and infectious diseases. Bridging the gap between disruptive
discovery products and real-world patient reach, we identify high-potential
compounds and technologies for in-licensing, clinically demonstrate their
safety and efficacy and then select large pharmaceutical commercialization
partners to maximize patient access globally.
For more information, please visit www.debiopharm.com
We are on Twitter. Follow us @DebiopharmNews at
http://twitter.com/DebiopharmNews
Debiopharm Contact
Dawn Haughton-Bonine
Communication Manager
dawn.bonine@debiopharm.com
Tel: +41 (0)21 321 01 11
Source: Debiopharm International SA
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。